Advanced glycation end-products as potential triggering factors of self-reactivity against myelin antigens in Multiple Sclerosis

Objectives To compare serum levels of the receptor for advanced glycation end products (sRAGE) between multiple sclerosis (MS) patients and healthy control subjects, and to investigate whether serum sRAGE levels correlate with MS disease severity as indicated by the Kurtzke Expanded Disability Status Scale (EDSS). Method 37 patients with clinical diagnosis of MS and 22 healthy control subjects were investigated in a cross-sectional study using enzyme-linked immunosorbent assays (ELISA). Results Serum levels of sRAGE were found to be significantly lower in MS patients compared to levels in healthy controls ( p = 0.005). A trend toward lower levels of serum sRAGE was observed in female MS patients compared to their male counterparts ( p = 0.05). A relationship between sRAGE and EDSS, and sRAGE and rate of clinical relapse was observed ( p = 0.012). Conclusion The significant reduction of sRAGE in MS patients relative to healthy controls supports the potential role for RAGE axis in MS clinical pathology. Lower levels of sRAGE may be associated with enhanced inflammatory responses. Based on these observations, further investigations into the role of sRAGE in MS clinical pathology is warranted.

Download Full-text

Soluble Receptor for Advanced Glycation End Products (sRAGE) is Up-Regulated in Multiple Sclerosis Patients Treated with Interferon β-1a

Cellular Physiology and Biochemistry ◽

10.1159/000488622 ◽

2018 ◽

Vol 46 (2) ◽

pp. 561-567 ◽

Cited By ~ 6

Author(s):

Mahnoosh Rahimi ◽

Sarah Saadat Aghabozorg Afjeh ◽

Mir Davood Omrani ◽

Shahram Arsang-Jang ◽

Maziar Ganji ◽

...

Keyword(s):

Multiple Sclerosis ◽

Advanced Glycation End Products ◽

Healthy Subjects ◽

Clinical State ◽

Enzyme Linked Immunosorbent Assay ◽

Inflammatory Disorder ◽

Advanced Glycation ◽

Glycation End Products ◽

End Products ◽

Multiple Sclerosis Patients

Background/Aims: Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system. Considering the role of immune system in its pathogenesis, researchers have focused on evaluation of the expression of immune-related genes or proteins in MS patients. Among proteins whose participation in inflammatory process has been documented is the receptor for advanced glycation end products (RAGE). Methods: In the present study, we compared RAGE transcript levels by means of quantitative real-time PCR as well as the serum level of soluble RAGE (sRAGE) by means of enzyme- linked immunosorbent assay (ELISA) in 50 IFNβ-1a responsive relapsing-remitting MS patients when compared with age and sex-matched healthy subjects. Results: Elevated expression of RAGE as well as higher levels of sRAGE were detected in IFN-β responsive MS patients compared with the controls. A significant inverse correlation between sRAGE plasma concentrations and the expanded disability status scale (EDSS) was also detected in which each unit of increase in sRAGE level resulted in a 0.308 unit decrease in EDSS. Conclusion: Considering the stable clinical state of the MS patients in this study and their response to IFNβ-1a, the elevated levels of sRAGE in patients compared with healthy subjects could be related to the effects of this kind of treatment.

Download Full-text